The overall range of the Trumpchi E9 is satisfactory. During testing, we observed that the vehicle was driven in smart hybrid mode, and the engine only started working when the battery level was below 20%. In addition, the vehicle used a 25-degree battery and a 56-liter fuel tank, which gave it a combined range of around 800 kilometers.
In the past September, China’s auto market once again handed over a beautiful "report card", and auto production and sales have shown growth for six consecutive months. Against the backdrop of the global auto industry being hit by the pandemic, the rapid recovery of China’s auto market undoubtedly provides a good model for the recovery of the global auto market.
However, under the premise that the domestic auto market is recovering well, the market share of Chinese brand passenger cars has shown a decline, falling to 36.4% from January to September, a year-on-year decrease of nearly 2.3 percentage points.
"The sales performance of Chinese auto brands is directly related to the trend of the auto market in the fourth quarter." An industry expert expressed the above judgment to Securities Times Car Capital.
Securities Times · Car Capital noticed that in the process of major Chinese auto brands struggling to turn around the decline, FAW Hongqi has achieved a contrarian growth that far exceeded market expectations. In September, monthly sales exceeded 20,000 vehicles, an increase of 86% year-on-year. This is a huge contrast with its sales performance in previous years.
Why did FAW Hongqi’s sales rise against the trend? What enlightenment will its growth bring to more Chinese auto brands and even the entire industry? It has become a hot topic in the industry recently.
Thunder reform works
"The competition in the entire manufacturing industry is intense, and it is more organic when it is dangerous. We saw such a prospect in FAW. Your development this year is unique."
On July 23, the top leader of the General Secretary of the Central Committee of the Communist Party of China, the President of the State, and the Chairperson of the Central Military Commission praised the red flag, the representative of the national brand, during a visit to the General Research and Development Institute of China FAW Group.
In the context of the "black swan" epidemic in China’s auto market for two consecutive years, the rise of FAW’s red flag against the trend can indeed be called "the unique scenery here".
A few days ago, China FAW announced sales data in September, Hongqi brand sales reached 21,500, an increase of 85.9%; 1-9 cumulative sales of 130,000, an increase of 104.4%. In 2019, Hongqi brand sales achieved nearly 600% year-on-year growth, cumulative sales exceeded 100,000.
Compared with the sluggish sales performance in earlier years, these two sets of data are like a "shocking reversal". What exactly did the Hongqi brand rely on to achieve a breakthrough against the trend? This has not only become a hot topic within the automotive industry, but also a hot topic for some investors.
An Qingheng, director of the China Automobile Industry Advisory Committee, told Securities Times Car Capital that the soaring sales of FAW Hongqi are closely related to its internal reforms in the past two years.
In September 2017, Xu Liuping, chairperson of FAW Group, who had been in office for less than two months, launched the Thunder Reform and adjusted the Hongqi brand to be directly operated by the group headquarters.
"This time the reform movement is particularly large. The original FAW Technology Center has been delisted, but the R & D General Institute, the Modeling Design General Institute, the New Energy Development Institute, and the Intelligent Networking Development Institute have been established respectively." An employee of FAW Group headquarters told Securities Times Che Capital on condition of anonymity that after the new organizational structure was completed, the group also carried out a "all stand up and compete for posts" personnel reform, and more than 4,000 cadres and employees at the headquarters had to be re-hired through competition.
At the beginning of 2018, the previous system reform quickly bore an important fruit – China FAW released the new Hongqi brand strategy. It is worth noting that at this press conference, China FAW called out the sales target of Xinhongqi, that is, 100,000 units in 2020, 300,000 in 2025, and 500,000 in 2035.
"Although the industry has not publicly discussed the sales target set by Xinhongqi, there are still many doubts." An Qingheng told Securities Times Car Capital that practice has proved that this series of reform policies has effectively promoted the development of Hongqi. Objectively speaking, Xu Liuping, as the helm of the company, played a key role.
An industry insider told Securities Times Car Capital that although the market share of Chinese brand passenger cars has declined and most of them face challenges, in general, there is still a strong entrepreneurial spirit in the industry, and the overall reform atmosphere is strong. Each brand is seeking transformation in line with the "new four modernizations" of the industry.
"It should be said that the revival of the Hongqi brand has exported a positive sample to the Chinese auto industry." An Qingheng believes that the successful transformation of Hongqi has brought inspiration to more independent brands and provided an upward path for reference.
Who is buying the Red Flag car?
"I was in my early 30s this year and bought a Hongqi H5 in 2019. At that time, I mainly liked the design and configuration of this car. You can’t enjoy this configuration by buying a joint venture car at the same price." Mr. Zhang, who lives in Zaozhuang, Shandong Province, told Securities Times Car Capital that in addition to high cost performance, what he values most is the overall tonality of the Hongqi brand. "Driving a Hongqi car, you seem to be very stable, and you have more face and personality," Mr. Zhang said.
Previously, people’s impression of Hongqi models was mostly "inspection cars" or concierge executive cars, which seemed to have little direct connection with the market. But with the launch of Hongqi H5, H7, HS5, HS7, H9 and other models in the past two years, this existing "stereotype" is gradually disintegrating.
A person close to China FAW told Securities Times Car Capital that according to his understanding, there are generally two types of consumers who buy Hongqi brand models. One is the more emotional and supportive, and the purchase of Hongqi cars is very national pride; the other is the more trendy consumer group. In recent years, the products launched by the Hongqi brand are more recognizable and can meet the personalized needs of consumers who pursue "different".
Pan Helin, executive dean and professor of the Digital Economy Research Institute of Zhongnan University of Economics and Law, told Securities Times Car Capital that the Hongqi brand has a deep historical sedimentation, and in this round of reform, FAW has made a good excavation of the value of the Hongqi brand. More importantly, the current market has undergone tremendous changes, and consumers’ car purchase preferences and habits are changing and becoming more diverse. This fundamental change in consumption trends will bring opportunities to Chinese car brands.
Indeed, in recent years, the rise of the national tide, Li Ning boarded the New York Fashion Week, the Forbidden City lipstick was snapped up, the white rabbit toffee, and the leap white shoes ushered in the red… Buying domestic products has become an emerging trend. Some analysts have pointed out that the rise of the national tide is not only related to the rise of young consumer groups and changes in consumer trends, but more importantly, it is closely related to the overall rise of national cultural self-confidence. Consumers can find a sense of satisfaction and belonging by purchasing domestic products full of cultural connotations.
The same is true of returning to the auto industry. At a Hongqi brand 4S store on Yaojiayuan Road in Beijing, a customer looking at the car told Securities Times Car Capital: "In recent years, Chinese brand models have improved in terms of design and product quality, especially the technology configuration is quite awesome. Driving Chinese brand models makes me feel quite proud."
Securities Times Car Capital noticed that even on weekdays, the Hongqi 4S shop is very busy, with consumers constantly coming to see the cars, and most of them are family units. "If it is on weekends, there will be a lot of consumers around every exhibition car, and there will be a queue when entering the cockpit to see the interior." Sales staff at Beijing Longze Hongqi Automobile Sales Co., Ltd. told Securities Times Car Capital.
In the most prominent position in the exhibition hall of this Hongqi 4S store, there is a Hongqi H9 that has just been listed. The above sales staff told Securities Times Car Capital that the new car has only been on the market for one month, and the order will be queued. At present, the most advanced configuration will take two months, and the personalized configuration will take almost half a year to pick up the car.
From little attention to ordinary consumers to monthly sales of 20,000 vehicles, the Hongqi brand has really moved to the end point market and completed its self-transformation.
"High-end is the right move!"
In the past period of time, some independent brands relied on price advantages to seize the market, and sales performance was also very good. But after a careful study of the pricing system of Hongqi’s main models, it will be found that "winning at a low price" is not the path chosen by Hongqi. Take Hongqi H7 as an example, its official guide price is 252,800 yuan – 317,800 yuan, and the newly listed Hongqi H9 has a guide price range of 309,800 yuan – 539,800 yuan. Obviously, the "200,000 yuan pricing ceiling" that continues to plague independent brand brands is being broken by Hongqi.
The salesperson in the Hongqi 4S store told Securities Times Car Capital that buying Hongqi’s new models does not require a price increase to pick up the car, which is a hard and fast rule of the manufacturer. However, Hongqi also rarely engages in promotional activities, and the price is relatively firm.
"Hongqi basically does not engage in promotions, and our discounts are more reflected in after-sales." The above-mentioned salesperson told Securities Times Car Capital that the purchase of Hongqi owners enjoys a lifetime free warranty service. At the same time, at the level of used car replacement, Hongqi can give the same value preservation rate as other luxury brands, relieving consumers of car replacement troubles.
Pan Helin said that in recent years, the Hongqi brand has made great efforts in marketing and channel construction, especially through the digital management model to transform the service chain, which has provided important support for the growth of sales.
It is not difficult to see that the re-started Hongqi brand is fully positioning itself as a luxury brand. In fact, many industry authorities have automatically included the Hongqi brand in the luxury brand camp in the process of ranking the sales list of automobile companies. In September, Hongqi successfully exceeded the monthly sales of 20,100 vehicles with 21,500 sales performance.
Industry insiders believe that compared with other independent brands, Hongqi’s high-end road has a natural brand advantage. An Qingheng told Securities Times Car Capital that the competition in China’s auto market is very fierce at present, and some mid-to-low-end enterprises have been gradually eliminated by the market, but independent brands, including, and so on, continue to move up and carry out high-end transformation. In his opinion, Hongqi’s sales have risen sharply against the trend, which further reflects the strength of Chinese auto brands and fully verifies the importance of high-end independent brands.
Shengang Securities analysis pointed out that the current Chinese auto brand products are no longer limited to low-price competition, and the idea of brand upward is becoming more and more obvious. Among them, higher profit levels are the driving force for brand upward.
Securities Times Car Capital learned that, taking Volkswagen Group as an example, the profit level of Volkswagen Group’s Volkswagen brand in 2019 was 4.3%, while the profit margin of its luxury brand was nearly twice that, reaching 8.1%, and the more luxurious brand reached 16.2%.
At the same time, Shengang Securities also analyzed that the solid growth of China’s automobile market in recent years has provided a solid foundation for Chinese automobile brands to move up the brand, and has also brought sufficient capital and technology accumulation space to enterprises.
However, An Qingheng also stressed that China’s auto market is very large, with both high-end and low-end markets. Companies should target precise market segments according to their own positioning. At the same time, whether it is high-end or low-end, the most important thing is to improve product quality. This is the foundation for building brand power and influence.
Yesterday morning, Lin Chaoxian’s film "Breaking the Wind" opened a media tour at the Hong Kong Velodrome, starring Peng Yuyan, Cui Siyuan, Wang Luodan and others in attendance. Ke Zhendong and Jaycee Chan’s drug abuse incident caused a lot of uproar. Peng Yuyan admitted that he is quite familiar with both of them. Regarding this matter, he said that now is the time for the two to be noticed and need the most care, and "I hope everyone is willing to give them another chance". Cui Siyuan, who has just finished filming Jackie Chan’s new drama "Lion from the Sky", said that Jackie Chan is very busy and has not contacted him about this matter, so it is inconvenient to respond.
Peng Yuyan made it clear that he would not take drugs
Peng Yuyan admitted that he is very familiar with Ke Zhendong and Jaycee Chan. "Among them, Ke Zhendong was known to us before he entered the industry, and he is also a very good friend. He is very polite in life." After the "landlord" drug abuse incident, many Peng Yuyan fans left messages on Weibo hoping that he would not take drugs. Peng Yuyan said that he "of course not. Everyone has stress, but there are many ways to relieve it. My own way is to choose a healthy way, and I hope everyone has a positive attitude. Cycling can also relieve stress."
Peng Yuyan said that for the "landlord" two people now, "the most important thing is that they are also responsible for what they do. I have known them for a long time, but what they did was really wrong. I believe that their relatives are the saddest now. I hope everyone is willing to give them another chance."
Wang Luodan is not afraid of being upstaged by younger generations
Just after the filming of "Huang Feihong: Heroes Have Dreams", Wang Luodan collaborated with Peng Yuyan again in "Breaking the Wind". Both plays have emotional scenes, but she said that with Peng Yuyan in the film is the stage of "less than full lovers". "Huang Feihong’s film is more emotionally tolerant. This play is passionate and youthful, and the emotional expression should be more external, but it is also good that our focus is to truly show the state of athletes." Speaking of whether he would spread rumors with Peng Yuyan, Wang Luodan said with a smile that he would rather "spread rumors" with Ouyang Nana, who plays a talented cyclist in the film, because she is more "fresh meat" than Peng Yuyan.
Ouyang Nana’s performance in "Beijing Love Story" is eye-catching. Facing the younger generation, Wang Luodan said that he is not afraid of being upstaged. "I want to protect her more, because she is still young and has just entered the industry. I am like a sister. I have discussed with her. I don’t want her to get involved in emotional dramas too early. After the age of 18, I will have time to take this kind of drama. I hope she will take some simple dramas quietly and beautifully." (Reporter, Chen Shuang)
On March 18, the Medici Innovative Pharmaceutical Industry Ecological Cooperation Conference with the theme of "20 Years of Beauty, Creating the Future Together" was successfully held in Shanghai Zhangjiang Science Hall. After 20 years of hard work, Medici (688202) has taken empowering biomedical innovation research and development as its mission, grown side by side with China’s biomedical industry, and has developed into a leading one-stop biomedical pre-clinical R & D service platform in China.
At the conference, more than 500 industry leaders from various fields such as government, industry, academia, and finance gathered to participate in the grand event. Together, they reviewed Medisi’s outstanding history over the past 20 years, witnessed the launch of its globalization prelude, and the grand launch of two key technology service platforms. In addition, the conference also held a number of thematic dialogues around current hot topics. The guests brainstormed and discussed in depth the future development direction of the innovative drug industry ecology. They offered suggestions for the sustainable development of the industry, pointed out the way forward, and worked together to explore new opportunities for the cooperative development of Chinese pharmaceutical companies.
Twenty Years of Prosperity Starting from "New" with high hopes
First of all, Mr. Wu Qiang, member of the Standing Committee of the Shanghai Pudong New Area District Committee and deputy head of the district, delivered a warm opening speech, expressing his heartfelt congratulations on Medici’s brilliant achievements over the past 20 years. He deeply reviewed how Medici participated in and witnessed the rapid development of the biomedical industry in Pudong, established an academician innovation drug ripening center, was approved by large enterprises to open an innovation center, and made outstanding contributions to the construction of the new drug empower ecosystem, and eagerly looked forward to Medici’s ability to continue to expand the breadth and depth of the industry and promote the vigorous development of the biomedical industry more widely. Finally, Vice Mayor Wu Qiang said that Pudong New Area will unswervingly promote institutional reform, provide a broader development space and more powerful policy support for the biomedical industry, and call on entrepreneurs and investors to come to Pudong to join hands in creating a new future of technological innovation!
Song Ruilin, executive chairperson of the China Pharmaceutical Innovation Promotion Association, pointed out in his speech that in the context of the reshaping of the global economic structure and the increasingly complex geopolitical situation, China’s biomedical industry is standing at a critical crossroads, facing both unprecedented challenges and huge development opportunities. In recent years, with the successive introduction of a series of policy plans, China’s biomedical industry has ushered in an unprecedented spring breeze of development, while Medicis and others will usher in a more rapid development momentum and contribute more to the rise of the biomedical industry. Finally, President Song Ruilin confidently emphasized that 2024 will be a year of hope for the biomedical industry.
Chen Chunlin, founder and CEO of Medici, expressed his sincere gratitude to all the guests in his speech. He mentioned that Medici has been fortunate to witness the rise of China’s biomedical industry and has achieved outstanding results in scientific research innovation, industrial integration and business expansion. He stressed that the current biomedical industry is ushering in a new spring, full of unlimited opportunities. As an important part of new drug research and development, Medici shoulders the important task of promoting the implementation of source innovation and empowering the development of the industry. Dr. Chen said that Medici looks forward to working with more partners to jointly build an ecological empowering circle and promote the sustainable innovation and development of the biomedical industry.
Chen Kaixian, an academician of the Chinese Academy of Sciences, delivered a wonderful keynote report, entitled "Biomedical R & D Innovation and Industrial Development", which deeply analyzed the opportunities and challenges of biomedical innovation and development, and comprehensively sorted out the situation, progress and problems of biomedical development in our country. He elaborated on the four major development trends of global pharmaceutical innovation, and keenly pointed out the shortcomings and bottlenecks in the field of biomedical development in our country. At the same time, Academician Chen also shared the hot spots of scientific and technological innovation, especially the application of artificial intelligence in the field of new drug research and development, which brought dawn to the research and development of new drugs. Finally, we look forward to strengthening cooperation from all walks of life and contributing to Shanghai’s goal of building a source of biomedical technology innovation and a world-class biomedical industry cluster.
The prelude to globalization has begun, deeply empowering the transformation of innovation achievements
Next, the prelude to a new chapter of globalization was officially opened, and the Transformation Ceremony of Medici’s Biomedical Source Innovation Achievements opened. This landmark moment not only fully demonstrates Medici’s outstanding innovation achievements in the field of biomedicine, but also indicates that these achievements will be quickly transformed into strong actual productivity, injecting new vitality and momentum into global cooperation and development, and enabling the drug research and development industry chain to innovate at the source and extend globally!
At the ceremony, Pharma representative Zhang Lianshan, research institute representative Li Bin, CXO industry representative Chen Chunlin, Zeng Dewan, Rong Yiping, AI intelligent medicine representative Zhang Long, overseas Biotech representative Mr. Sam Waksal, domestic Biotech representative Cheng Changfu, Liu Binlei, investor representative Zhao Yongsheng came to the stage one after another to join hands to start the transformation of biomedical source innovation achievements. Medici will take this launch ceremony as an opportunity to further strengthen communication and cooperation with domestic and foreign partners, jointly explore new paths for the transformation of biomedical innovation achievements, and work together to promote the sustainable prosperity and development of the global biomedical industry, and jointly create a better future.
Next, Mr. Sam Waksal shared his views on the original innovation of the biopharmaceutical industry and the globalization of innovative drugs, saying that under the leadership of Dr. Chen, Medici has developed over the past two decades and has become a leader in the industry, and its achievements are remarkable. Although the biomedical industry is young, it has shown great potential and influence on a global scale, driving sustained economic growth. Today, the pharmaceutical and biotechnology fields are closely linked, and they are jointly committed to the research and development of innovative drugs. Medici has played a pivotal role in it, not only transcending national borders and politics, but also injecting new vitality into the global economy. Finally, we look forward to the future to continue to witness their greater contributions to human health and economic development.
Innovative drug going overseas strategy and successful case sharing
Innovative drugs continue to go overseas, how to seize the global market? Under the chairpersonship of Qiangjing, founder & chairperson of Xinnuowei and founding partner of Xingze Capital, Zhang Lianshan, deputy general manager and president of global R & D of Hengrui Pharmaceutical, Xue Tongtong, founder, chairperson and CEO of Yilian Bio, Peng Jianbiao, president of Jimin Trustworthy Small Molecular Innovation Research Institute, Pan Wensen, partner of the Hong Kong office of Gaowin International Law Firm, and Lin Qingcong, executive vice president and president of the US company of Medici, industry leaders gathered together to discuss the strategy and path of innovative drugs going overseas.
Zhang Lianshan, Xue Tongtong, and Peng Jianbiao shared their respective strategic plans and successful experiences in innovative drugs going overseas from the perspective of pharmaceutical companies. They elaborated on how to achieve global distribution of innovative drugs through precise positioning, technological innovation, and international cooperation, providing useful inspiration for pharmaceutical companies.
From the legal perspective, Penvenson deeply analyzed the legal challenges and coping strategies faced by innovative drugs going overseas. He emphasized the importance of compliance and provided practical legal advice to the participants.
As an investor and a representative of pharmaceutical companies, Qiangjing shared Xinnovi’s unique experience in innovative drug research and development and internationalization, and said that Xingze Capital has been paying attention to the research and development and industrialization of innovative drugs, providing funds and resources for potential enterprises and projects, and promoting the globalization process of China’s innovative drugs.
Lin Qingcong shared the rich experience and profound lessons of Medici in assisting pharmaceutical companies to enter the international market from the perspective of CRO. He emphasized that Medici’s one-stop biomedical pre-clinical R & D service platform can support the whole process of drug discovery from target discovery to IND declaration. In addition, the new drug empower ecosystem of the Academician Innovative Drug Ripeness Center can help new drug funding, transactions and other issues. At present, Medici has established a research and development base in Boston, which will further empower the drug to go overseas and achieve higher value.
Multi-site blockbuster unveiling Two key technology platforms released
At this grand ceremony, Medici’s two major science and technology platforms made a major appearance, attracting extensive attention from the participants.
1. Drug Discovery & Pharmaceutical Research Science Key Technology Platform
Jian Liu, President of Medici’s Drug Discovery and Pharmacy Research Division, introduced the Drug Discovery & Pharmacy Research Science Key Technology Platform. The platform includes a new drug platform for targeted protein degradation, a small nucleic acid drug development platform, an ADC drug development platform, a polypeptide macrocyclic peptide drug development platform, an AI drug development platform, a synthetic biology platform, a green chemistry platform, a drug metabolite platform, etc., to support the innovation of various drug forms. It is worth noting that Medici has a complete R & D platform for small molecule innovative drugs; an AI drug discovery platform empowers and accelerates new drug development from target discovery to the generation of preclinical compounds; a green chemistry platform and a synthetic biology platform enable the synthesis of various complex compounds.
2. Key technology platform for preclinical research science
Subsequently, Zhang Haizhou, president of Medici’s preclinical research division, elaborated on Medici’s key technology platform for preclinical research science. In terms of discovery biology, Medici has built in vitro screening platforms, such as PROTAC, small nucleic acids, ADC, etc., as well as cutting-edge technologies such as synthetic biology and nano-antibody discovery. In terms of pharmacological efficacy, there are advanced platforms such as in vivo imaging, small animal surgical excision, and in vitro imaging. In addition, Zhang Haizhou focused on introducing DMPK and safety service platforms for various advanced drug types such as PROTAC, oligonucleotide, ADC, mRNA, and cellular immunity, as well as pre-clinical service platforms such as inhalation medication, ophthalmic medication, and topical medication.
The release of the two key technology service platforms not only fully demonstrates the outstanding strength and profound heritage of Medici in the field of biomedical pre-clinical research and development, but also provides a solid and powerful support for its future customers to better empower.
Industry leaders gather together A new blueprint for biomedicine
Frontier technologies and industrial applications of drug discovery
How to promote the transformation of basic scientific research results in China? What are the future development trends? Ma Dawei, academician of Chinese Academy of Sciences and researcher of Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Tao Weikang, vice president and general manager of global innovative drug research and development of Qilu Pharmaceutical Group, Liu Dongzhou, general manager of CSO/Innovative Drug Global R & D Center of East China Pharmaceutical, Shen Hong, head and senior vice president of Roche China Innovation Center, and Xu Yaochang, chairperson and CEO of Yuyu Pharmaceutical, shared their insights from their respective fields. Liu Jian, president of Medici Drug Discovery & Pharmaceutical Research Division, moderated this keynote dialogue.
Faced with the difficulty of transforming basic research, Ma Dawei shared in depth the course of cooperation with Academician Medisi’s Innovative Pharmaceutical Refinement Center, believing that this cooperation has achieved remarkable results in the transformation of scientific and technological achievements, bringing a mutually beneficial and win-win situation to both parties. At the same time, Shen Hong, head of Roche China Innovation Center and senior vice president, also introduced the Roche Accelerator, the world’s first self-established and operated accelerator project. The project fully integrates Roche’s own resources and advantages, and provides start-ups with all-round support including funding channels, cooperation opportunities, R & D experience, and advanced experimental equipment in an agile and flexible way to help start-ups grow rapidly and promote the development and industrialization of innovative drugs.
Tao Weikang, Liu Dongzhou, Shen Hong, Xu Yaochang and other pharmaceutical company leaders, based on the practical experience of their respective companies, discussed in depth how to accurately grasp their own advantages and differentiate the layout of innovative drug industry pipelines. They stressed that each company should formulate R & D strategies according to its core competitiveness. Facing the ever-changing technological challenges and changing future development trends, they said that pharmaceutical companies need to maintain keen insight and keep up with the pace of industry development. In sharing, they not only showcased the fruitful results achieved by their respective companies in the field of innovative drugs, but also provided valuable experience and inspiration for the future development of China’s innovative drug industry.
Transformation of new technologies for preclinical research of innovative drugs
Under the chairpersonship of Peng Shuangqing, Chief Scientific Officer of Medici, an in-depth discussion on the transformation of new technologies in preclinical research of innovative drugs was launched. The conference focused on breaking through the model barriers in preclinical research, technology development trends, market demand and future challenges, achievement transformation, and multi-party linkage.
Xu Zengjun, the former chief scientist of the Drug Evaluation Center of the State Food and Drug Administration and the founder of AstraZeneca Medicine, deeply analyzed the multiple challenges of preclinical research, such as the lack of understanding of the principle, mechanism and predictive correlation between models and diseases, as well as drug regulatory issues. Xia Mingde, founder/chairperson/CEO of Innolake Pharmaceutical, deeply analyzed the key role of translational medicine in crossing the "valley of death" in new drug development, and also pointed out the key role of translational medicine in crossing the "valley of death". Dr. Wang Yaning, former director of the clinical pharmacology department of the US FDA and CEO of Langlai Technology, pointed out that the FDA is cautious about preclinical data. Although AI technology is applied, there is insufficient data. It is necessary to optimize methods, strengthen translational research and data cooperation to improve R & D efficiency. Wang Haisheng, founder/chairperson/CEO of Sihe Genomics, emphasized the importance of AI in understanding the structure of genes and RNA, and mentioned the challenge of genetic differences between animal models and humans and the attempt of new organoid technologies. Yang Xiaobao, founder/chairperson/CEO of Bioscience, shared his research and development experience in the field of protein degradation, emphasized the importance of safety evaluation in preclinical research, and mentioned that with the help of Medici’s one-stop preclinical service platform, they successfully obtained clinical approval in China and the United States. Finally, he emphasized the enlightenment of tracking the layout of large companies such as MNC for Biotech.
Following the glorious past, we will move towards a glorious tomorrow. This 20th anniversary celebration of Medici is not only a feast for a full house, but also a brainstorming that concerns the development of the next 20 years. In the past two decades, Medici has not only witnessed the magnificent development history of the industry, but also acted as a vanguard force driving the continuous upgrading of the industry. In the future, Medici will adhere to innovation, deepen the field of biomedical pre-clinical research and development, lead technological innovation, enrich the matrix of R & D service platforms, layout the global market, ride the wind and waves, and move forward in the next two decades! (CIS)
Proofreading: Wang Jincheng
[car home Information] car home has learned that (|) will debut on December 27th. The new car is the first model of Starway M3X Mars Architecture 2.0, positioned as a medium-sized SUV with a 2.0T engine, and PHEV models will be launched in the future.
In terms of appearance, the front face of Starway Eta Ursae Majoris adopts a three-dimensional middle net design, and the middle net is composed of a diamond that grows from small to large, and at the same time, it is designed in one color with the body, similar to the design of electric vehicles. At the same time, the middle of the two headlights is penetrated by a decorative plate with English logo, and there is a penetrating decoration above the headlights. The daytime running lights form a 7-shape and are connected with the air inlets on both sides, and the headlights are designed with lenses.
On the side of the car body, the new car adopts a sporty coupe SUV shape. The whole car body is slender, and the roof is constantly pressed down. The door handle adopts a hidden design, and the rim is similar to the rim design of an electric car. In terms of body size, the length, width and height of the car are 4781/1920/1671mm and the wheelbase is 2815 mm.
At the rear of the vehicle, the new car is designed with penetrating taillights. At the same time, the star LOGO of the new car is also hidden in the headlights. The rear fog lights are located on both sides of the car body, plus the exhaust from both sides, which looks very sporty.
In terms of interior, the new car adopts a sporty interior style design, and the air conditioning knob of the center console looks extremely chic, even with the taste of a sports car. The car is equipped with a 24.6-inch curved dual screen, and the steering wheel is designed with touch control, which is very simple as a whole. It is reported that the car will be equipped with Qualcomm 8155 intelligent cockpit chip and Horizon J3 driver-assisted chip, which supports functions such as WHUD, ARHUD and 50W mobile phone charging.
In terms of configuration, Eta Ursae Majoris offers five models to choose from, of which the two-wheel drive versions are standard, comfortable and distinguished, among which the standard version is equipped with 19-inch aluminum alloy wheels, ambient light, wireless charging of 50W mobile phone, NFC key, panoramic image, full-speed ACC/AEB, electric tailgate, 8-speaker stereo, front electric seat and so on. The four-wheel drive version is available in comfort and distinguished versions. We noticed that it will also be equipped with CDC adaptive electromagnetic suspension system, ARHUD and so on.
In terms of power, the new car will be equipped with a 2.0TGDI engine with a maximum power of 261 HP (192 kW) and a maximum torque of 400 Nm, matching the 7DCT gearbox, and a PHEV model will be launched in the future. (Text/car home Xing Yueyang)
1905 movie network news Directed by, starring, and released a group of role posters, and announced that it would be released on November 30, taking the lead in preheating the market at the end of the year and firing the first shot of the New Year. In the poster, there is a full screen of online public opinion, which is full of all kinds of people who don’t know the truth and endless condemnation and abuse. Zhou Dongyu, Song Yang and Yuan Hong are in the complicated public opinion field and have their own thoughts. I look forward to the film’s release on November 30th.
In the previous premiere activities, this film "pointing to reality" won many praises, such as "cyber violence", "public opinion reversal" and "choosing a concubine on campus", and all kinds of sharp realistic topics made the audience bluntly say that "the film shines into reality". Some viewers said, "The perpetrators do whatever they want, the victims are arguing, and the truth of online public opinion is inseparable, which not only makes people feel numb, but also deserves our good taste and thinking." The director also said at the scene, "Some time ago, the fire rescued many fraud victims, and I hope that" Hot Search "can also be a fire, so that the era of irresponsible voice on the Internet will pass."
A public opinion game of "smoke everywhere"
Audience: Did we influence public opinion or did public opinion influence us?
Is the school sponsored by the big group actually a "paradise for choosing a concubine" for the rich? In the movie, Chen Miao (Zhou Dongyu), He Yan (Song Yang), Peng Yue (Justin) and others launched a battle of online public opinion around the "industrial chain of choosing a concubine on campus" caused by a girl jumping off a building. Although there is no sword and shadow, the tit-for-tat between the forces of good and evil and the constant reversal of public opinion have made many viewers bluntly say "innovative", "substituted" and "thoughtful". "Deducting all sentient beings under the flow, whether we have influenced public opinion or public opinion has influenced us?"
Director Xin Yukun has always been good at digging deep into realistic themes, while Hot Search shows the story behind public opinion from a novel perspective. Some viewers expressed their surprise after watching the movie. "When you are purely a bystander, you see that there are so many unknown secrets behind the ever-changing public opinion events." Some viewers said, "The protagonist seems to be a character, but in fact, the sharp and ruthless comments behind it are the real protagonist of this film."
A bloody story of "Mayflies shake trees"
Audience: You may not be Chen Miao, but you can be her fellow traveler.
The film "Hot Search" tells a story of speaking out for the weak and confronting the powerful, and also depicts the people behind the "hot search". In the film, Chen Miao (Zhou Dongyu), the editor-in-chief of the media, took the lead in tearing off the false mask of the wealthy businessman and declaring war on the unjust power. However, it was backstab, a teammate of He Yan (Song Yang), and Yue Peng, an investor (Justin) who suppressed her. Digging black materials, hanging hot searches, splashing dirty water ….. Faced with all kinds of threats, Chen Miao is still indomitable, and wants to reshape the unfair "rules". The audience also said that they were "moved by Chen Miao’s courage".
After watching the movie, many viewers described it as a story of "flying flies shaking trees". "You can’t help being angry, you will feel empathetic powerlessness, and you will have desperate feelings and blood." The self-media team led by Chen Miao tried their best to speak out for the truth, and was also rated as a just alliance on the Internet by the audience. Their courage and fearlessness inspired many viewers, saying that "it may not be Chen Miao, but it can be Chen Miao’s fellow traveler".
The film Hot Search will be released nationwide on November 30th.
Reporter Huai Xiao Intern Liu Xiaolu
What kind of surprise will "Butterfly Queen" Zhang Yufei bring in the final battle of the year? hair
From December 10th to 15th, the 2023 National Swimming Championships will be staged in the swimming pool of Jinan Olympic Sports Center. As the trials of the 2024 Doha Swimming World Championships and the Paris Olympic Games, this event is the most important local single event in China swimming this year, and it is also the final work of the China Swimming Army in 2023.
At that time, China’s top swimmers will gather in Quancheng, and Qin Haiyang, Wang Shun, Zhang Yufei, Yang Junxuan, Xu Jiayu, Pan Zhanle and Li Bingjie will show their elegance in Quancheng Jinan. This weekend, come to the Olympic Sports Center to see the flying people in the swimming pool!
The "frog king" returned with honor.
Male model debuts
The rise of China Swimming Army in 2023 has a great relationship with Qin Haiyang. In October this year, he just won the title of Best Male Swimmer of the Year of the World Swimming Federation, which is the first time that China athletes have won this honor.
Being recognized by FINA shows that Qin Haiyang’s performance is brilliant enough. This year, he won 23 gold medals in Fukuoka World Championships, Chengdu Universiade, Hangzhou Asian Games and FINA World Cup, creating a myth in breaststroke.
In this national swimming championship, Qin Haiyang signed up for three individual events: 50-meter breaststroke, 100-meter breaststroke and 200-meter breaststroke, and will appear at Jinan Olympic Sports Center on the 10th, 12th and 14th.
For Qin Haiyang, the stage of the National Swimming Championships is no stranger. As early as 2018, he won the 200-meter breaststroke championship. This time again, Qin Haiyang is expected to achieve all the gold medals.
Wang Shun, the big brother in the swimming corps, has maintained a high competitive level for many years. In this national swimming championship, Wang Shun signed up for the individual events of 100m backstroke, 200m backstroke, 100m breaststroke, 100m butterfly and 200m individual medley. There are so many events that he can be called a "model worker."
Wang Shun and Jinan Swimming Pool are old acquaintances. In 2019, Wang stood on the FINA World Cup Jinan Station, but missed the championship medal. After four years, Wang Shun will never allow himself to be disappointed when he returns to Jinan again.
Xu Jiayu, who set a new record of 52.23 seconds in the men’s 100m backstroke at the Hangzhou Asian Games, will also compete in the 100m backstroke and 400m freestyle at the Jinan Olympic Sports Center.
Of course, the new generation also has strong players. For example, at the Asian Games in Hangzhou, Pan Zhanle, who opened the 100-meter 47-second mark in men’s freestyle, will make an all-round attack in five events: 50m freestyle, 100m freestyle, 200m freestyle and 200m backstroke.
For Pan Zhanle, swimming is a simple matter of "jumping into the water and winning". This makes people wonder, how fast can he swim this time?
"Butterfly Queen" outshines others.
Can the veteran still eat?
This year, the only female swimmer in China can compete with Qin Haiyang, only "Butterfly Queen" Zhang Yufei, both of whom won 23 gold medals in this year’s international competition.
In this national swimming championship, Zhang Yufei will participate in five individual events, including women’s 50m freestyle, 100m freestyle, 50m butterfly, 100m butterfly and 200m butterfly. With a total of six days’ schedule, Zhang Yufei will play in the preliminary and final matches on five competition days (December 10th, 11th, 13th, 14th and 15th).
Zhang Yufei, 25, has entered the second half of her career, but at present, no matter which event she plays, she has the ability to win all the gold medals, and her competitive state is excellent.
Besides Zhang Yufei, the most surprising thing this year is the strong return of veteran Ye Shiwen.
At the London Olympic Games in 2012, Ye Shiwen was crowned as the "double champion" of women’s 200m individual medley and 400m individual medley, reaching a peak in her sports career. However, after that, she was affected by injury and illness, and fell into a trough, far from the public eye.
After that, Ye Shiwen retired, came back, retired again and came back again, and never stayed away from swimming. At this year’s Asian Games in Hangzhou, Ye Shiwen won one gold and one silver, announcing his return. In this competition, Ye Shiwen will appear in the 100m breaststroke, 200m freestyle and 400m individual medley. Today, Ye Shiwen is still competitive in medley and breaststroke.
In addition, Li Bingjie, Yu Yiting and other new generations will also appear in Quancheng. Among them, Li Bingjie signed up for five events: 200m freestyle, 400m freestyle, 800m freestyle, 1500m freestyle and 200m butterfly. At present, she has strong dominance in Asian women’s middle and long distance events.
Yu Yiting, who is only 18 years old, will compete in 11 events, such as the 200m individual medley, 100m butterfly and 50m breaststroke. This little girl with multi-line attack will also win more attention in Jinan Olympic Sports Center.
Fight at home
Qilu athletes strive for good results
For Shandong swimmers, what they are most looking forward to is undoubtedly Yang Junxuan, who plays at home.
This year, Yang Junxuan has not fought much, but his strength is still online. At the Asian Games in Hangzhou, Yang Junxuan won 2 gold medals and 1 silver medal, and achieved the best personal record in the 100-meter freestyle upstream, showing an excellent competitive state.
As a grand slam winner of Olympic Games, World Championships, Short-course World Championships, World Cup, Youth Olympic Games, Asian Games, National Games and Military Games, Yang Junxuan is not only the pride of Shandong, but also an indispensable member of China Swimming Army.
In Taiyuan Station, Shanxi Province, the National Swimming Championships in 2018, the fledgling Yang Junxuan won the women’s 100-meter freestyle championship. Now she is fighting at home, and her goal is more honor.
In this competition, Yang Junxuan will compete in 50m freestyle, 100m freestyle and 200m freestyle. As a short-distance swimmer, it goes without saying that 100m freestyle is her dominant event. In the 200-meter freestyle, Yang Junxuan’s performance has also made steady progress in recent years. At present, if she can maintain a good competitive state, it is not impossible to win gold at home.
In addition, Ji Xinjie will also participate in this national swimming championship. In recent years, Ji Xinjie’s performance is not excellent, but there is always a feeling of untimely birth.
Previously, in the field of men’s long-distance freestyle, Ji Xinjie, who is the best player in Asia at least, has been shrouded in the aura of Sun Yang and cannot shine his own light because of Sun Yang. In the 2017 National Games in Tianjin, Ji Xinjie won five silver medals in a row, which is an absolute "sad hero".
Now, Ji Xinjie, who is 26 years old, is a veteran of the China Swimming Army. This year, he won only the sixth place in the men’s 200m freestyle in the National Swimming Championships. This time at home, can Ji Xinjie hand over a satisfactory "answer sheet"? It is worth looking forward to.
Sprint to Paris
Can it bring surprises?
Due to FINA’s special schedule for the new World Championships (to be held in February next year) and to avoid being too close to the Asian Games, this year’s national championships will be held in mid-December. The specifications of this tournament are higher than in previous years, which is equivalent to the national championship. As a trial for the World Championships, no domestic active master was absent from this tournament.
This year’s competition is not only in line with the international competitions such as the World Championships and the Olympic Games, but also adopts the latest standards of FINA. Its purpose is to let the contestants test the training effect in the actual combat environment, and also to train for the World Championships in Doha and the Paris Olympic Games.
At present, the China Swimming Team still has great hope to surprise the Chinese people again in the World Championships and Olympic Games next year.
Among them, Qin Haiyang and Zhang Yufei are both in their prime and have the strength to compete for the gold medal; If Wang Shun and Xu Jiayu can adjust to the best condition, there is also hope to compete for medals.
After 00, represented by Yang Junxuan, Pan Zhanle, Li Bingjie and Yu Yiting, they also have the strength to compete for gold and silver in their respective advantageous projects through many competitions. Next year in Paris, they are expected to gain a more stable position in the national team.
Considering that Zhang Yufei and Qin Haiyang are among the best in the world, people will naturally look forward to next year’s World Championships in Doha and China Swimming in the Paris Olympic Games.
Great changes have taken place in the lineup of Houston Rockets this summer. One of the disappointments is that the Rockets sold usman Garba, Josh Christopher and Ty Washington. Their development this year was daunting and almost wasted.
Among them, usman Garba also accepted an interview with the media after joining the Thunder, revealing that he especially wanted to go to the Thunder when he was in the draft. The former Rockets center complained that he didn’t get enough chances, and Thunder is a team that suits him very well.
As the No.23 rookie in the first round of 2021, Ousmane Garouba was plagued by injuries in his first season without playing, averaging only 2 points and 3.5 rebounds per game. In the Rockets, his overall performance is not satisfactory. However, Osman Garba represented Spain in last year’s men’s basketball European Cup. At that time, his overall performance was excellent. Osman Garba also served as the main rotation inside player to help Spain win the men’s basketball European Cup. However, after returning to the NBA, Osman Garba could not win the trust of then head coach Steve Cyrus, so he had to play as a substitute and his playing time was scarce. Usman Garba has been in a low state all season. He averaged 3 points, 4.1 rebounds and 0.9 assists per game. His data is average, but Osman Garba’s efficiency is high, especially his defensive potential.
However, the Rockets seem to have no patience to train usman Garba, who was easily sold cheaply in the offseason and finally came to the Thunder. Osman Garba said that he had already made contact with Thunder coach Daniolt and general manager Presti, and believed that they would benefit a lot from Thunder’s tactical system, and the two sides reached an agreement on many issues.
In addition, Garba, usman, like the Rockets, the Thunder also looks very competitive. Shea Kirghiz-Alexander, Josh Giddy, Chet Holmgren and Rugenzdort are all young, and I believe we are a team. Usman Garba admired them very much. However, even usman Garba expressed his hope to be selected by the Thunder, which already has Chet Holmgren, Robinson Earle, Poksevsky and Davidson Bertain, so the situation has not changed at all. For usman Garba, staying in Oklahoma City is not easy.
When it comes to the comparison between Kobe and Jordan, most people think that Jordan is the first shooting guard in the NBA, Kobe is the second shooting guard in the NBA, and Jordan is in front of Kobe, which is not controversial.
When it comes to the comparison between James and Jordan, most people think that Jordan is ahead of James; But some people think that James should be ahead of Jordan.
The reason why there is such a big difference is not because James is better than Kobe, but because of the track problem.
Kobe’s choice is to catch up with Jordan head-on. His route is similar to Jordan’s, and even his playing style and style are close to Jordan’s. In this case, Jordan has six champions and six FMVPs, and Kobe has five champions and two FMVPs, so everyone thinks that Jordan won and Kobe lost.
James’ choice was to find another way. The route he took was different from Jordan’s, and even this road was not traveled by many people. In the end, James achieved some "first" achievements on his own road, but many NBA stars including Jordan didn’t, so James did what they didn’t do, so comparing from different angles, naturally James could be ahead of Jordan.
The most typical example is that James is the first player in NBA history to get FMVP from three different teams, but Jordan, Duncan, Russell, Bird, Jabbar and other stars can’t even get together with three teams. From this perspective, James is indeed the first person in history.
This is also the reason why in the first-person vote in history, Kobe got less votes and James got more votes.
Take the World Cup group match as an example. In the 2022 World Cup group match, the first in Group E is Japan, the second is Spain, the first in Group F is Morocco, and the second is Croatia.
Jordan is Morocco and Kobe is Croatia. They are very comparable. In contrast, Jordan is in the lead, so there is no suspense in the ranking. Jordan is the first and Kobe is the second.
James is Japan, and he is on his own way, and he is also the first. Durant and Harden are similar to James’ route. Obviously, they are all behind James.
When choosing the strongest team in the group stage, no one will choose Croatia because it has Morocco in front of it, but someone will choose Japan because it is also the first in the group. But can you say that Japan, which ranks first in Group E, must be better than Croatia, which ranks second in Group F?
Obviously not.
This is Kobe’s paranoia.
In fact, there was only one person in Kobe’s pursuit, that is Jordan. He just wanted to catch up with Jordan. As for the others, he didn’t care. For him, he either surpassed Jordan or didn’t surpass him. That’s all. In his cognition, there is no difference between the second place and the 100th place, so he can say that the second place is the biggest loser.
Of course, there was another one he wanted to surpass, and that was O ‘Neill …
James, on the other hand, is more rational and smarter.
Perhaps he wanted to catch up with Jordan’s path in the early days, but after realizing the difficulty, he chose another one. On this road, James was one of the pioneers, and finally he succeeded and became the leader of this road.
You can’t say that James’s other way is bad. After all, many imitators followed James’s old path, but their achievements were not as high as James’s, such as Durant.
And James is also trying to collect all kinds of "firsts" to increase his chips for the GOAT.
There are many criteria for the selection of the GOAT, among which James is the GOAT, but in fact, from a competitive point of view, Jordan is undoubtedly the GOAT, which is the fundamental reason why Jordan has a very high position in the NBA.
Huang Renfan, who proved himself in Europe, is also interested in Inter Milan and Rangers.
European teams are paying more and more attention to Huang Renfan.
Huang Renfan is a type player with a large amount of activities and accurate shooting, which has become the vitality of the team. Born in 1996, he made his mark in Daejeon Citizen Team, and grew up step by step after Vancouver White Hat Team and Rubin Kazan. Then he moved to Olympiacos in Greece before the 2022-23 season.
Then through the world cup, it grew to another level. Ren Huang Fan Ceng is the main midfielder of the Korean national team led by head coach Paolo Vento. A large number of activities, building capacity, and watching the game have also been fully exerted on the world stage, and they are active as the protagonists of the top 16 Korean companies.
This season, he is also the core midfielder of the team Olympiacos. In the 2022-23 season, Huang Renfan won the trust of head coach Mitchell in 32 games, 3 goals and 4 assists in the Greek League. Although it is not Jose now, but the coaching system has changed, it still takes the core as the core. Huang Renfan also continues to be active in Europe and is associated with many clubs. In Italy, Inter Milan have been linked together. Huang Renfan of the Greek media "Temporary Gazzetta" has attracted the attention of many people in Inter Milan. It is said that before the new season, he was selected into the signing list of Inter Milan.
Inter Milan’s interest has continued. Since January this year, Inter Milan has sent scouts to Greece to observe Huang Yinfan. It is reported that Huang Yinfan has entered the next transfer market.
Following Inter Milan, Rangers have recently been linked with Huang Renfan. "Rangers can compete with Inter Milan for South Korean national team player Huang Renfan," said Rangers News, which reported the news of Rangers.
However, it is also predicted that it is difficult for Rangers to compete with Inter Milan. "Wanderers News" explained: "Whether Rangers can compete with Inter Milan, which entered the UEFA Champions League (UCL) final in the transfer market, and whether they can win in the end is still unknown." Inter Milan beat AC Milan 1-0 at 4 am (Korea time) on the 17th and entered the Champions League final.